Location of Repository

Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants

By Rachel P. J. Lai, Michael S. Seaman, Paul Tonks, Frank Wegmann, David J. Seilly, Simon D. W. Frost, Celia C. LaBranche, David C. Montefiori, Antu K. Dey, Indresh K. Srivastava, Quentin Sattentau, Susan W. Barnett and Jonathan L. Heeney


Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA), are known to be potent, their toxicity and reactogenicity make them unacceptable for human use. Here, we explored different adjuvants and compared their ability to elicit antibody responses to FCA/FIA. Recombinant soluble trimeric HIV-1 gp140 antigen was formulated in different adjuvants, including FCA/FIA, Carbopol-971P, Carbopol-974P and the licensed adjuvant MF59, or combinations of MF59 and Carbopol. The antigen-adjuvant formulation was administered in a prime-boost regimen into rabbits, and elicitation of antigen binding and neutralizing antibodies (nAbs) was evaluated. When used individually, only FCA/FIA elicited significantly higher titer of nAbs than the control group (gp140 in PBS (p<0.05)). Sequential prime-boost immunizations with different adjuvants did not offer improvements over the use of FCA/FIA or MF59. Remarkably however, the concurrent use of the combination of Carbopol-971P and MF59 induced potent adjuvant activity with significantly higher titer nAbs than FCA/FIA (p<0.05). This combination was not associated with any obvious local or systemic adverse effects. Antibody competition indicated that the majority of the neutralizing activities were directed to the CD4 binding site (CD4bs). Increased antibody titers to the gp41 membrane proximal external region (MPER) and gp120 V3 were detected when the more potent adjuvants were used. These data reveal that the combination of Carbopol-971P and MF59 is unusually potent for eliciting nAbs to a variety of HIV-1 nAb epitopes

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3324409
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2000). A phase
    2. (2001). A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.
    3. (1999). A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant.
    4. (1995). A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
    5. (1999). A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
    6. (1995). Adjuvants for human vaccines–current status, problems and future prospects.
    7. (1997). An investigation of the highavidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.
    8. (2010). Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.
    9. (2011). Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
    10. (1994). Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant.
    11. (1989). Atlantic Treaty Organization. Scientific Affairs Division
    12. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
    13. Chemical aspects of drug delivery systems: Royal Society of Chemistry.
    14. (1994). Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
    15. (2006). Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
    16. (1998). Dendritic cells internalize vaccine adjuvant after intramuscular injection.
    17. (2006). Evidence of breed-dependent differences in susceptibility to porcine circovirus type-2-associated disease and lesions.
    18. (1997). Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
    19. (2009). Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.
    20. (2011). Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
    21. (2009). Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIVA New Potent Adjuvant Combination PLoS
    22. (1994). Handbook of pharmaceutical excipients.
    23. (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
    24. (2010). Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
    25. (1996). In-vitro bioadhesion of carbopol hydrogels.
    26. (1930). Insoluble Precipitates in Diphtheria and Tetanus Immunization.
    27. (1996). MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.
    28. (2007). MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    29. (2009). MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
    30. (2003). MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    31. (1995). MF59. Design and evaluation of a safe and potent adjuvant for human vaccines.
    32. (2002). Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    33. (2010). New adjuvants for human vaccines.
    34. (2011). Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.
    35. (2008). Phase 1 trial of malaria transmission blocking vaccine candidates
    36. (2010). Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.
    37. (2010). Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer.
    38. (2009). Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.
    39. (2002). Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
    40. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
    41. (2004). Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.
    42. (2005). Revisiting Freund’s incomplete adjuvant for vaccines in the developing world.
    43. (2004). Rheological, mucoadhesive and release properties of Carbopol gels in hydrophilic cosolvents.
    44. (1990). Rubinstein A
    45. (2000). Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
    46. (2001). Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.
    47. (2009). Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.
    48. (2010). Suvaxyn M.hyo Suspension for injection for pigs. http://wwwnoahcompendiumcouk/Pfizer_Limited/documents/S3979html Accessed
    49. (1988). The ability by different preparations of porcine parvovirus to enhance humoral immunity in swine and guinea pigs.
    50. (2010). The role of antibodies in HIV vaccines.
    51. (2009). The tissue compatibility of different Mycoplasma hyopneumoniae vaccines is mainly dependent upon their adjuvants.
    52. (2007). The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.
    53. (2012). Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.
    54. (2007). Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
    55. (2011). Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.
    56. (2007). Vaccine adjuvants and delivery systems.
    57. (2000). Vaccine adjuvants: preparation methods and research protocols.
    58. (2010). Vaccine adjuvants: putting innate immunity to work.
    59. (2010). Very few substitutions in a germ line antibody are required to initiate significant domain exchange.
    60. (2008). Wack A

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.